Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2023Research and Practice in Thrombosis and HaemostasisOpen Access

Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa

View Full Paper
Ask AI
Bookmark
Share

Authors

TLToshko LissitchkovNational Specialized Hospital for Active Treatment of Hematologic DiseasesAWAnnemieke WillemzeSanofi (Netherlands)CJChristelle JanSanofi (France)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lissitchkov et al. (2023) studied this question.

synapsesocial.com/papers/6a20d52ffd936e2c9649c951https://doi.org/10.1016/j.rpth.2023.100176
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study2021 · 48 citations
  2. 2BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A2020 · 140 citations
  3. 3Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients2019 · 32 citations
  4. 4Methods for individualising factor VIII dosing in prophylaxis2014 · 35 citations
  5. 5Phase I study of BAY 94‐9027, a PEGylated B‐domain‐deleted recombinant factor VIII with an extended half‐life, in subjects with hemophilia A2014 · 144 citations